References
Barrett JC, Hansoul S, Nicolae DL et al (2008) Genome-wide association defines more than
30 distinct susceptibility loci for Crohn’s disease. Nat Genet 40:955–962
Bouvier AM, Sant M, Verdecchia A et al (2010) What reasons lie behind long-term survival
differences for gastric cancer within Europe? Eur J Cancer 46(6):1086–1092
Chao C (2012) Overview of personalized medicine in GI cancers. J Gastrointest Surg 16
(9):1641–1644
Chong E, Ensom MH (2003) Pharmacogenetics of the proton pump inhibitors: a systematic
review. Pharmacotherapy 23(4):460–471
Coenen M, van Marrewijk C, Derijks L et al (2014) Personalized thiopurine dosing based on
TPMT genotyping reduces leucopenia occurrence and results in cost-savings in IBD patients.
Results from a randomized trial in the Netherlands. J Crohns Colitis 8(Suppl 1):S4
D’Haens G, Baert F, van Assche G et al (2008) Early combined immunosuppression or conven-
tional management in patients with newly diagnosed Crohn’s disease: an open randomised
trial. Lancet 371(9613):660–667
Dignass A, van Assche G, Lindsay JO et al (2010) The second European evidence-based
consensus on the diagnosis and management of Crohn’s disease: current management. J
Crohns Colitis 4(1):28–62
Dossumbekova A, Prinz C, Rad R et al (2006) Helicobacter pylori outer membrane proteins and
gastric inflammation. Gut 55:1360–1361
European Association for the Study of the Liver (2014) EASL practice guidelines: management of
hepatitis C virus infection. J Hepatol 60(2):392–420
Ge D, Fellay J, Thompson AJ et al (2009) Genetic variation in IL28B predicts hepatitis C
treatment-induced viral clearance. Nature 461(7262):399–401
Gill SR, Pop M, De Boy RT et al (2006) Metagenomic analysis of the human distal gut
microbiome. Science 312:1355–1359
Guttmacher AE, Collins FS (2002) Genomic medicine – a primer. N Engl J Med 347:1512–1520
Hagymasi K, M€ullner K, Hersze ́nyi L et al (2011) Update on the pharmacogenomics of proton
pump inhibitors. Pharmacogenomics 12(6):873–888
Hamburg MA, Collins FS (2010) The path to personalized medicine. N Engl J Med 363:301–304
Hunfeld NG, Mathot RA, Touw DJ et al (2008) Effect of CYP2C192 and 17 mutations on
pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol
65(5):752–760
Issa A (2007) Personalized medicine and the practice of medicine in the 21st century. Mcgill J
Med 10(1):53–57
Lynch HT, Lynch JF, Lanspa SJ (2010) Familial pancreatic cancer. Cancers 2(4):1861–1883
Malfertheiner P, Megraud F, O’Morain CA et al (2012) Management of Helicobacter pylori
infection – the Maastricht IV/Florence Concensus Report. Gut 61:646–664
Markowitz SD, Bertagnolli MM (2009) Molceular basis of colorectal cancer. N Engl J Med
361:2449–2460
Mendoza JL, Abreu MT (2009) Biological markers in inflammatory bowel disease: practical
consideration for clinicians. Gastroenterol Clin Biol 33(Suppl 3):S158–S173
Miki D, Ochi H, Hayes CN et al (2012) Hepatocelullar carcinoma: towards personalized medicine.
Cancer Sci 103(5):846–850
Morrow MP, Pankhong P, Laddy DJ et al (2009) Comparative ability of IL-12 and IL-28B to
regulate Treg populations and enhance adaptive cellular immunity. Blood 113(23):5868–5877
Ozawa S, Soyama A, Sawada J et al (2004) Ethnic differences in genetic polymorphisms of
CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 19:83–95
Panaccione R, Ghosh S (2010) Optimal use of biologics in the management of Crohn’s disease.
Therap Adv Gastroenterol 3(3):179–189
Patel KP, Babyatsky MW (2008) Medical education: a key partner in realizing personalized
medicine in gastroenterology. Gastroenterology 134:656–661
Personalized Medicine in Gastroenterology 263